Company intelligence / Profile preview

Chrysantis

Ownership: Private
Development stage: Commercial

Overview

Chrysantis developed high-purity zeaxanthin from marigolds using natural breeding methods. Their zeaxanthin product has been evaluated in at least one completed clinical trial for visual function in atrophic age-related macular degeneration patients. The company supplies these carotenoids as nutraceutical ingredients rather than prescription drugs. This marks the first time that naturally sourced, high-purity zeaxanthin was available on the market—a significant advance in the nutraceutical industry targeting eye health.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Food & Nutrition

Drug pipeline

5 assets

ezeyes 5% oil suspension

Commercial

Indications: Eye health

4 more assets in the full pipeline.

Request access →

Partnerships

Ball Horticultural CompanyUniversity of Utah

Beyond the preview

Go deeper on Chrysantis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chrysantis.

Explore the full profile